Sirolimus (rapamycin), an mTOR pathway inhibitor, was recently identified as beneficial for patients with KHE and VCR-resistant and -refractory or recurrent life-threatening KMP [5]. The gene discussed is MTOR; the disease is kaposiform hemangioendothelioma.